| Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis E Rumi, D Pietra, C Pascutto, P Guglielmelli, A Martínez-Trillos, I Casetti, ... Blood, The Journal of the American Society of Hematology 124 (7), 1062-1069, 2014 | 484 | 2014 |
| Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies PM Maciocia, PA Wawrzyniecka, B Philip, I Ricciardelli, AU Akarca, ... Nature medicine 23 (12), 1416-1423, 2017 | 238 | 2017 |
| Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy F Da Roit, PJ Engelberts, RP Taylor, ECW Breij, G Gritti, A Rambaldi, ... haematologica 100 (1), 77-86, 2015 | 183 | 2015 |
| Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study PL Zinzani, A Santoro, G Gritti, P Brice, PM Barr, J Kuruvilla, ... Journal of Clinical Oncology, JCO. 19.01492, 2019 | 179 | 2019 |
| Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial F Perrone, MC Piccirillo, PA Ascierto, C Salvarani, R Parrella, AM Marata, ... Journal of translational medicine 18 (1), 405, 2020 | 151 | 2020 |
| Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab A Rambaldi, G Gritti, MC Micò, M Frigeni, G Borleri, A Salvi, F Landi, ... Immunobiology 225 (6), 152001, 2020 | 146 | 2020 |
| Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities CF Magnani, G Gaipa, F Lussana, D Belotti, G Gritti, S Napolitano, ... The Journal of clinical investigation 130 (11), 6021-6033, 2020 | 131 | 2020 |
| Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 E Brunetta, M Folci, B Bottazzi, M De Santis, G Gritti, A Protti, SN Mapelli, ... Nature Immunology 22 (1), 19-24, 2021 | 130 | 2021 |
| Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support G Gritti, F Raimondi, D Ripamonti, I Riva, F Landi, L Alborghetti, M Frigeni, ... | 127 | 2020 |
| Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma P Armand, A Janssens, G Gritti, J Radford, J Timmerman, A Pinto, ... Blood, The Journal of the American Society of Hematology 137 (5), 637-645, 2021 | 93 | 2021 |
| IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study G Gritti, F Raimondi, D Ripamonti, I Riva, F Landi, L Alborghetti, M Frigeni, ... Medrxiv, 2020.04. 01.20048561, 2020 | 86 | 2020 |
| Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas S Cortelazzo, C Tarella, AM Gianni, M Ladetto, AM Barbui, A Rossi, ... American Society of Clinical Oncology 34 (33), 4015-4022, 2016 | 86 | 2016 |
| Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial A Cortelezzi, M Sciumè, AM Liberati, D Vincenti, A Cuneo, G Reda, ... Leukemia 28 (3), 642-648, 2014 | 71 | 2014 |
| The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy A Rambaldi, C Boschini, G Gritti, F Delaini, E Oldani, A Rossi, AM Barbui, ... American journal of hematology 88 (12), 1062-1067, 2013 | 71 | 2013 |
| Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma PL Zinzani, IW Flinn, SLS Yuen, MS Topp, C Rusconi, I Fleury, K Le Dû, ... Blood, The Journal of the American Society of Hematology 136 (23), 2628-2637, 2020 | 68 | 2020 |
| GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA F Bonfiglio, A Bruscaggin, F Guidetti, L Terzi di Bergamo, M Faderl, ... Hematological Oncology 39, 2021 | 59 | 2021 |
| Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status A Cortelezzi, G Gritti, N Del Papa, MC Pasquini, R Calori, U Gianelli, ... Leukemia 22 (3), 646-650, 2008 | 57 | 2008 |
| Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 G Gritti, F Raimondi, B Bottazzi, D Ripamonti, I Riva, F Landi, L Alborghetti, ... Leukemia 35 (9), 2710-2714, 2021 | 53 | 2021 |
| SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model L Ceriani, G Gritti, L Cascione, MC Pirosa, A Polino, T Ruberto, A Stathis, ... Blood Advances 4 (6), 1082-1092, 2020 | 52 | 2020 |
| Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the … E González-Barca, A Boumendil, D Blaise, M Trněný, T Masszi, H Finel, ... Bone Marrow Transplantation 55 (2), 393-399, 2020 | 44 | 2020 |
Alessandro RambaldiProfessore di Ematologia, Università degli Studi di Milano在 unimi.it 的电子邮件经过验证
